Stereotaxis, INC 8-K filings

Stereotaxis announced robust second-quarter 2026 results, with robotic catheter revenue surging 270% sequentially, alongside strategic acquisitions and positive future outlook for profitability.

Stereotaxis has finalized its acquisition of Robocath, integrating French robotic technology to enhance its surgical robotics offerings.

Stereotaxis, Inc. successfully concluded its 2026 Annual Meeting of Shareholders, confirming the election of three directors and the ratification of its independent auditor.

Stereotaxis announced its first quarter 2026 financial results, highlighting regulatory approvals for new products and a strategic acquisition, while revenue declined year-over-year.

Stereotaxis, Inc. announced its definitive agreement to acquire Robocath, a French robotic technology innovator, for an initial consideration of $20 million and potential earnout payments up to $25 million.

Stereotaxis reports Q3 2025 financial results, highlighting new robotic system orders, FDA clearance for GenesisX, and progress in its catheter portfolio.

Stereotaxis, Inc. has entered into a sales agreement with Roth Capital Partners, LLC to sell up to $50 million of common stock through an at-the-market offering.

Stereotaxis reported a 95% year-over-year revenue increase in Q2 2025, driven by strong system and recurring revenue growth, alongside key regulatory approvals and a recent equity financing.

A leading surgical robotics company has announced a $12.5 million registered direct offering of common stock, led by a strategic industry partner, to bolster its balance sheet and fund innovation.

A medical technology company anticipates significant sequential and year-over-year revenue growth for its second quarter, driven by increases in both recurring and system revenues.

Stereotaxis, Inc. held its Annual Meeting of Shareholders on May 15, 2025, and elected two Class III directors and ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for fiscal year 2025.

Stereotaxis announced a 9% increase in revenue for Q1 2025, driven by a 29% rise in recurring revenue, and highlighted key commercial and innovation milestones.

Stereotaxis reports a strong Q4 2024 with a 39% revenue increase and positive cash flow, driven by robotic system revenue and the integration of Access Point Technologies (APT).

Stereotaxis reported an 18% year-over-year revenue increase in the third quarter of 2024, driven by demand for its Genesis robotic systems and the acquisition of Access Point Technologies.

Stereotaxis reported financial results for the second quarter of 2024 that fell below expectations, despite significant progress in strategic innovation and a confident outlook for the second half of the year.

Stereotaxis, Inc. finalized its acquisition of Access Point Technologies EP, Inc. on July 31, 2024, issuing 1,486,620 shares of common stock as part of the deal.

Stereotaxis has appointed Nachum Homi Shamir, a seasoned executive with a strong track record in medical device companies, to its Board of Directors.

Stereotaxis, Inc. has agreed to acquire Access Point Technologies EP, Inc., a company specializing in diagnostic catheters, in a deal expected to close in the third quarter of 2024.

Stereotaxis announced its first quarter 2024 financial results, showing revenue growth and an increase in system backlog, alongside the acquisition of Access Point Technologies to expand its catheter capabilities.

Stereotaxis reported a challenging 2023 with revenue declines, but anticipates significant growth in 2024 driven by new product launches and a strong system backlog.